Discordant effects of guanidines on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats - PubMed (original) (raw)
Discordant effects of guanidines on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats
J R Nyengaard et al. Diabetes. 1997 Jan.
Abstract
We examined the effects of aminoguanidine and methylguanidine on vascular dysfunction, glomerular structural changes, and indexes of early and late nonenzymatic glycation in 7-month streptozotocin-induced diabetic rats. Kidney weight, glomerular volume, fractional mesangial volume, glomerular capillary basement membrane width, and urinary albumin excretion were increased in diabetic rats. Diabetes also 1) increased vascular albumin permeation twofold in retina, sciatic nerve, aorta, skin, and kidney; 2) decreased renal collagenase-soluble collagen; 3) increased collagen-associated fluorescence in kidney and skin but not in aorta; and 4) increased glycated hemoglobin levels and aortic pentosidine levels. Aminoguanidine reduced albuminuria by 70% after 4 months, and both guanidines 1) normalized aortic pentosidine levels and renal collagenase-soluble collagen, 2) had no effect on glycated hemoglobin levels or collagen-associated fluorescence (in aorta, kidney, or skin), and 3) had little or no effect on regional albumin permeation. These discordant effects of aminoguanidine on diabetes-induced vascular changes versus parameters of nonenzymatic glycation are consistent with a multifactorial pathogenesis of diabetic complications, including roles for metabolic imbalances independent of nonenzymatic glycation. To the extent that glomerular matrix accumulation and increased regional albumin permeation in chronically diabetic rats are sequelae of nonenzymatic glycation, these findings point to an important role for early glycation reactions and products.
Similar articles
- Dietary myo-inositol supplementation does not prevent retinal and glomerular vascular structural changes in chronically diabetic rats.
Tilton RG, Faller AM, LaRose LS, Burgan J, Williamson JR. Tilton RG, et al. J Diabetes Complications. 1993 Jul-Sep;7(3):188-98. doi: 10.1016/1056-8727(93)90044-y. J Diabetes Complications. 1993. PMID: 8343613 - Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats.
Tilton RG, Pugliese G, LaRose LS, Faller AM, Chang K, Province MA, Williamson JR. Tilton RG, et al. J Diabet Complications. 1991 Oct-Dec;5(4):230-7. doi: 10.1016/0891-6632(91)90082-z. J Diabet Complications. 1991. PMID: 1779018 - Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats.
Degenhardt TP, Fu MX, Voss E, Reiff K, Neidlein R, Strein K, Thorpe SR, Baynes JW, Reiter R. Degenhardt TP, et al. Diabetes Res Clin Pract. 1999 Feb;43(2):81-9. doi: 10.1016/s0168-8227(98)00121-1. Diabetes Res Clin Pract. 1999. PMID: 10221660 - Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy.
Cohen MP, Ziyadeh FN. Cohen MP, et al. J Am Soc Nephrol. 1996 Feb;7(2):183-90. doi: 10.1681/ASN.V72183. J Am Soc Nephrol. 1996. PMID: 8785386 Review. - Meloxicam fails to augment the reno-protective effects of soluble epoxide hydrolase inhibition in streptozotocin-induced diabetic rats via increased 20-HETE levels.
Katary MM, Pye C, Elmarakby AA. Katary MM, et al. Prostaglandins Other Lipid Mediat. 2017 Sep;132:3-11. doi: 10.1016/j.prostaglandins.2016.08.004. Epub 2016 Sep 3. Prostaglandins Other Lipid Mediat. 2017. PMID: 27596333 Review.
Cited by
- Advanced glycation end products and diabetic complications.
Singh VP, Bali A, Singh N, Jaggi AS. Singh VP, et al. Korean J Physiol Pharmacol. 2014 Feb;18(1):1-14. doi: 10.4196/kjpp.2014.18.1.1. Epub 2014 Feb 13. Korean J Physiol Pharmacol. 2014. PMID: 24634591 Free PMC article. Review. - Aminoguanidine prevents fructose-induced deterioration in left ventricular-arterial coupling in Wistar rats.
Chang KC, Liang JT, Tseng CD, Wu ET, Hsu KL, Wu MS, Lin YT, Tseng YZ. Chang KC, et al. Br J Pharmacol. 2007 Jun;151(3):341-6. doi: 10.1038/sj.bjp.0707223. Epub 2007 Apr 2. Br J Pharmacol. 2007. PMID: 17401443 Free PMC article. - Targeting advanced glycation with pharmaceutical agents: where are we now?
Borg DJ, Forbes JM. Borg DJ, et al. Glycoconj J. 2016 Aug;33(4):653-70. doi: 10.1007/s10719-016-9691-1. Epub 2016 Jul 9. Glycoconj J. 2016. PMID: 27392438 Review. - Differential effects of Smad3 targeting in a murine model of chronic kidney disease.
Kellenberger T, Krag S, Danielsen CC, Wang XF, Nyengaard JR, Pedersen L, Yang C, Gao S, Wogensen L. Kellenberger T, et al. Physiol Rep. 2013 Dec 15;1(7):e00181. doi: 10.1002/phy2.181. eCollection 2013 Dec 1. Physiol Rep. 2013. PMID: 24744860 Free PMC article. - Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention.
Brings S, Fleming T, Freichel M, Muckenthaler MU, Herzig S, Nawroth PP. Brings S, et al. Int J Mol Sci. 2017 May 5;18(5):984. doi: 10.3390/ijms18050984. Int J Mol Sci. 2017. PMID: 28475116 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources